Oncobiologics prices IPO at $6, as expected
Oncobiologics, which is developing biosimilars of blockbuster drugs Humira and Avastin, raised $35 million by offering 5.8 million units at $6.
Oncobiologics plans to list on the Nasdaq under the symbol ONS. Jefferies and Barclays acted as lead managers on the deal.
The article Oncobiologics prices IPO at $6, as expected originally appeared on IPO investment manager Renaissance Capital's web site renaissancecapital.com.
Investment Disclosure: The information and opinions expressed herein were prepared by Renaissance Capital's research analysts and do not constitute an offer to buy or sell any security. Renaissance Capital, the Renaissance IPO ETF (symbol: IPO) or the Global IPO Fund (symbol: IPOSX) , may have investments in securities of companies mentioned.